Role of PCSK9 inhibitors in the management of dyslipidaemia
Proprotein convertase subtilisin kexin9 (PCSK9) inhibitors are novel agents that lower LDL cholesterol and reduce cardio-vascular event rate. Being expensive, these agents are reserved for those with high risk or very high risk of CV events and with suboptimal response to statins and ezetimibe, with...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Elsevier
2024-03-01
|
| Schriftenreihe: | Indian Heart Journal |
| Schlagworte: | |
| Online-Zugang: | http://www.sciencedirect.com/science/article/pii/S0019483223004807 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|